Chart Advisor: Comparing Pfizer and the S&P 500

Articles From: Investopedia
Website: Investopedia

From SIA Charts

1/ Daily Stock Report: Pfizer Inc (PFE)

2/ Candlestick Chart

3/ Point and Figure Chart

Investopedia is partnering with CMT Association on this newsletter.  The contents of this newsletter are for informational and educational purposes only, however, and do not constitute investing advice. The guest authors, which may sell research to investors, and may trade or hold positions in securities mentioned herein do not represent the views of CMT Association or Investopedia. Please consult a financial advisor for investment recommendations and services.

1/ Daily Stock Report: Pfizer Inc

The last time we looked at Pfizer Inc (PFE) was a year ago on Jan 19, 2023, when the stock just entered the Red Unfavored Zone of the SIA S&P 100 Index report at a price of $46.08. The shares currently trade at $28.99. Since then, PFE had declined -36.36% in the past 1-year time frame and an annualized return of negative 25.41% for the trailing 2-year time frame. The corresponding S&P 500 index has increased 22.05% over the past 1 year and 1.20% over the past 2 years. Pfizer Inc (PFE), a Drug stock, currently sits dead last out of 103 spots in the SIA S&P 100 Index report, dropping 4 spots in the last quarter.

2/ Candlestick Chart

In looking at the 2 Year Candlestick Chart of Pfizer (PFE) the shares initially trended sideways from January 2022 to Jan 2023, then once the shares entered the unfavored Zone on Jan 17th, 2023, we see the bottom fall out of the shares and a steady downtrend of consistently lower lows and lower highs which is still intact up until today indicating an extended period of a long-term distribution phase. Which makes matters worse, in longer term downtrends, stocks tend to first form some sort of a basing pattern for a period of time before an uptrend can materialize which we don’t see occurring yet on PFE. SIA Charts also helps you identify other names for better opportunities in the Peer group. Elli Lilly, another Drug stock, entered the Green Favored on April 4th (it still resides in the Favored Zone) and is up 80.40% in the past 1 year, and has an annualized return of 57.49% in the past 2 years.

3/ Point and Figure Chart

In looking at the Point and Figure Chart at a 2% Scale, we see that the stock peaked back in December of 2021 at a price of approximately $56.08 and since then, after a brief sideways trading range in 2022, a steady decline of lower highs and lower lows formed beginning in 2023. After finding a brief support area at $35.00 in May to June of 2023, the shares broke down again, trading below its long-term downtrend line at the $32.00 area before finding a bottom at the $26.00 level. Currently we see the shares in a rising column of X’s, which has formed in the past month but a reversal in trend still has not materialized as yet and no sign of a confirmed bottom can be seen. 

Near-term resistance is fast approaching the 50% retracement level of $30.96 and, above that, $36.28 and $40.05. Support can be found at its 3-box reversal of $26.95 and, below that, its recent low at $25.91.

With a bearish SMAX score (which is a near-term 1 to 90-day indicator comparing an asset against different equal-weight asset classes) of 5 out of 10, PFE is exhibiting short-term weakness against the asset classes.

Originally posted 12th January 2024

Join the Discussion

Thank you for engaging with IBKR Campus. If you have a general question, it may already be covered in our FAQs. If you have an account-specific question or concern, please reach out to Client Services.

Your email address will not be published. Required fields are marked *

Disclosure: Investopedia

Investopedia.com: The comments, opinions and analyses expressed herein are for informational purposes only and should not be considered individual investment advice or recommendations to invest in any security or to adopt any investment strategy.  While we believe the information provided herein is reliable, we do not warrant its accuracy or completeness. The views and strategies described on our content may not be suitable for all investors. Because market and economic conditions are subject to rapid change, all comments, opinions and analyses contained within our content are rendered as of the date of the posting and may change without notice. The material is not intended as a complete analysis of every material fact regarding any country, region, market, industry, investment or strategy. This information is intended for US residents only.

Disclosure: Interactive Brokers

Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Investopedia and is being posted with its permission. The views expressed in this material are solely those of the author and/or Investopedia and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.